The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Jun 17, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new type of imaging test called 18F-G1 PET/CT, which helps doctors see how well immunotherapy is working in patients with different types of cancer, including solid tumors (like lung or breast cancer) and blood cancers. Immunotherapy is a treatment that helps the body’s own immune system fight cancer. The goal is to find out if this imaging test can better track the effects of immunotherapy and help guide treatment decisions.

People who might join this study are adults diagnosed with cancer who have not had immunotherapy before and have at least one tumor that can be measured. They should be healthy enough to receive immunotherapy and expected to live at least six more months. Women who are pregnant or planning to become pregnant cannot join. Participants will undergo the 18F-G1 PET/CT scan during their immunotherapy treatment to help doctors monitor their progress. It’s important to know that this study has not started recruiting yet, and only those treated at certain centers where the scan can be done within a specific time frame will be eligible. Participants will need to agree to use contraception during and for six months after the study and provide informed consent before joining.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team.
• • 2. Subjects didn't receive previous immunotherapy.
• • 3. There exists at least one measurable target lesion according to the RECIST 1.1.
• • 4. ECOG performance status≤2.
• • 5. The expected survival time is ≥6 months.
• • 6. Effective contraceptive measures will be adopted during the study period and within 6 months after the study.
• • 7. Willing and able to fully understand and sign the informed consent form.
• Exclusion Criteria:
• • 1. Women in the preconception period, pregnancy, or lactation period.
• • 2. Combined with other malignant tumor.
• • 3. Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy.
• • 4. Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency.
• • 5. Receiving radiotherapy or interventional therapy during the immunotherapy.
• • 6. 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.